Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Clonidine

Preparation Calculator

USE IF: Selected HTN / resistant HTN; withdrawal adjuncts; sympathetic overactivity β€” with BP/HR/sedation monitoring and taper plan.

AVOID IF: Severe bradycardia or high-grade conduction disease without pacing plan; inability to taper/monitor; known hypersensitivity.

Clonidine

Central Ξ±2-agonist (antihypertensive / sympatholytic)

AdultHTNWithdrawalICUSedationWardER

Indication

HTN (selected) β€’ Resistant HTN β€’ Withdrawal adjunct β€’ Sympathetic excess β€’ ADHD (specialist) β€’ Sedation adjunct

At a glance

INDICATIONS (CORE USE)

- Hypertension (selected; not first-line) - Resistant hypertension - Withdrawal syndromes (opioid / alcohol adjunct) - Sympathetic overactivity states - ADHD (specialist) - Sedation adjunct (selected ICU/ward)

ADULT DOSE (STANDARD)

HTN PO: start 0.1 mg BID β†’ titrate cautiously; typical 0.1–0.3 mg BID (individualize) Patch: weekly transdermal β€” dose per product; slow onset / steady-state Titrate slowly to limit hypotension and sedation; adjust in renal impairment

MAX DOSE

Protocol- and patient-dependent (no universal ceiling in this monograph)

Route

PO / transdermal patch

PEDIATRIC DOSE

Specialist use only

Do not miss

Must-not-miss safety points

Major warning

- Rebound hypertension if abruptly stopped (can be severe) - CNS depression / sedation (additive with other sedatives) - Bradycardia / hypotension risk - Overdose β†’ CNS depression, bradycardia, hypotension - Do NOT stop suddenly β€” taper required

Indications

Primary

  • Hypertension (selected cases; not first-line)
  • Resistant hypertension

Secondary

  • Withdrawal syndromes (opioid, alcohol adjunct)
  • Sympathetic overactivity states

Other

  • ADHD (specialist context)
  • Sedation adjunct (selected ICU/ward cases)

Dosing

STANDARD (ADULT PO)

HTN (adult PO): start 0.1 mg BID β†’ titrate cautiously; typical range 0.1–0.3 mg BID (individualize)

ADULT DOSE

Titrate slowly to avoid hypotension / sedation. Patch: weekly system β€” dose per product labeling; slower onset than PO. Renal impairment: prolonged effect β€” reduce / extend interval per clinical response and reference.

PEDIATRIC DOSE

Specialist use only

MAX DOSE

Protocol- / patient-dependent

Practical Note

- **Never stop abruptly** β€” taper per protocol - **Ξ²-blocker + clonidine:** if discontinuing both, stop **Ξ²-blocker last** (rebound HTN risk if clonidine stopped first) - PO ↔ patch switches require **overlap / bridge** per pharmacy–protocol (avoid coverage gaps)

Warnings

Clinical warnings

  • - Rebound hypertension if stopped abruptly
  • - Sedation / CNS depression
  • - Bradycardia / AV block risk
  • - Hypotension (especially with dose escalation)
  • - Dry mouth, fatigue (common)

Contraindications

  • - Severe bradycardia
  • - Significant conduction disease (without pacing)
  • - Known hypersensitivity

Drug interactions

  • - Other antihypertensives β†’ additive hypotension
  • - Beta-blockers β†’ ↑ rebound HTN risk if clonidine stopped first
  • - CNS depressants β†’ additive sedation
  • - TCAs β†’ may reduce clonidine effect

Special populations

Pediatrics

Specialist use only

Pregnancy

Pregnancy: use only when benefit outweighs risk per OB/specialist and labeling.

Lactation

excreted in milk β€” infant sedation possible; risk/benefit.

Renal impairment

Prolonged half-life β†’ dose / interval adjustment; reassess BP, HR, sedation after changes.

Hepatic impairment

Generally acceptable; monitor sedation and BP clinically.

Elderly

↑ sensitivity to sedation and hypotension β€” start low, titrate slowly.

Administration

- PO divided dosing - Patch: weekly application; slower steady-state than PO - PO ↔ patch transitions: **overlap strategy** per protocol β€” avoid abrupt gaps

Monitoring

  • Monitor: - BP - HR - Sedation level
  • Recheck: - After dose changes (reassess BP/HR/sedation) - During withdrawal or taper pathways (reassess frequently)
  • Hold if:
    - Symptomatic hypotension
    - Bradycardia
    - Excess sedation

Overdose / toxicity

Clinical Picture

- CNS depression (can mimic opioid toxicity) - Bradycardia - Hypotension

Immediate Actions

- Supportive care - Airway / breathing support if needed - Treat bradycardia / hypotension per ACLS / protocol

Antidote

- No specific antidote β€” naloxone may have variable effect; supportive care primary

Decontamination

Recent oral ingestion: supportive care; toxicology if altered mental status or hemodynamic instability.

Escalation

Refractory shock / airway failure β†’ ICU escalation per protocol.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

- Never stop abruptly β†’ rebound HTN - Always taper with BP/HR monitoring

Clinical pearls

- **Ξ²-blocker + clonidine:** stop **Ξ²-blocker last** when winding down both - Overdose can **mimic opioid toxicity** β€” differentiate clinically / workup

Pharmacy Tool

Preparation Calculator

Clonidine 0.1 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Central acting - Renal clearance significant (accumulation risk when renal function falls) - Patch provides smoother plasma levels vs immediate PO peaks

Mechanism of action

- Central Ξ±2 agonism β†’ ↓ sympathetic outflow

Common brand names

Saudi Arabia

Catapres, Dixarit

Global

Kapvay, Kapvay (ADHD example), (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA hypertension and special-population guidance (where applicable)
  • ASAM / institutional opioid and alcohol withdrawal protocols
  • FDA / SFDA product labeling (PO and transdermal)
  • ICU sedation / sympatholysis pathways (institution-specific)